The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
Open accessAbstract
Currently available HIV-1 protease inhibitors are potent agents in the therapy of HIV-1 infection. However, limited oral absorption and variable tissue distribution, both of which are largely unexplained, complicate their use. We tested the hypothesis that P-glycoprotein is an important transporter for these agents. We studied the vectorial transport characteristics of indinavir, nelfinavir, and saquinavir in vitro using the model P-glycoprotein expressing cell lines L-MDR1 and Caco-2 cells, and in vivo after intravenous and oral administration of these agents to mice with a disrupted mdr1a gene. All three compounds were found to be transported by P-glycoprotein in vitro. After oral administration, plasma concentrations were elevated 2-5-fold in mdr1a (-/-) mice and with intravenous administration, brain concentrations were elevated 7-36-fold. These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain. This raises the possibility that higher HIV-1 protease inhibitor concentrations may be obtained by targeted pharmacologic inhibition of P-glycoprotein transport activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTER
Gottesman, M. M., & Pastan, I. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002125 · Cited by 3,568
Schinkel, A. H., Smit, J. J. M., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., te Riele, H. P. J., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,281
Cordon-Cardo, C., O'Brien, J. P., Casals, D., Rittman-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750
Expression of a multidrug-resistance gene in human tumors and tissues.
Fojo, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.265 · Cited by 1,544
Schinkel, A. H., Wagenaar, E., Mol, C. A., & van Deemter, L. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118699 · Cited by 1,264
Schinkel, A. H., Wagenaar, E., van Deemter, L., Mol, C. A., & Borst, P. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118214 · Cited by 1,107
Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K. F., Borst, P., Nooijen, W. J., Beijnen, J. H., & van Tellingen, O. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.2031 · Cited by 882
Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and Zalcitabine
Collier, A. C., Coombs, R. W., Schoenfeld, D. A., Bassett, R. L., Timpone, J., Baruch, A., Jones, M., Facey, K., Whitacre, C., McAuliffe, V. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604183341602 · Cited by 745
HIV-1 protease inhibitors. A review for clinicians
Deeks, S. G. (1997) · JAMA · doi:10.1001/jama.277.2.145 · Cited by 675
Carpenter, C. C. J. (1996) · JAMA · doi:10.1001/jama.276.2.146 · Cited by 541
Cited by
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Mammalian ABC Transporters in Health and Disease
Borst, P., & Elferink, R. O. (2002) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.71.102301.093055 · Cited by 1,571
Leslie, E. M., Deeley, R. G., & Cole, S. P. C. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.10.012 · Cited by 1,406
Identification of functionally variant MDR1 alleles among European Americans and African Americans
Kim, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117412 · Cited by 1,009
Self-citationP-Glycoprotein, a gatekeeper in the blood–brain barrier
Schinkel, A. H. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00085-4 · Cited by 960
The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin
Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.-P., von Richter, O., Zundler, J., & Kroemer, H. K. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6663 · Cited by 917
Drug resistance in brain diseases and the role of drug efflux transporters
Löscher, W., & Potschka, H. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1728 · Cited by 900
Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance
Marzolini, C. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.012 · Cited by 895
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Lindenberg, M., Kopp, S., & Dressman, J. B. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.001 · Cited by 864
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Self-citationHirsch, M. S., Brun-Vézinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., et al. (2000) · JAMA · doi:10.1001/jama.283.18.2417 · Cited by 766
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Self-citationDeeley, R. G., Westlake, C., & Cole, S. P. C. (2006) · Physiological Reviews · doi:10.1152/physrev.00035.2005 · Cited by 761
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Pharmacogenomics and Individualized Drug Therapy
Eichelbaum, M., Ingelman-Sundberg, M., & Evans, W. E. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.56.082103.104724 · Cited by 720
Rational Use of in Vitro P-glycoprotein Assays in Drug Discovery
Polli, J. W., Wring, S. A., Humphreys, J. E., Huang, L., Morgan, J. B., Webster, L. O., & Serabjit-Singh, C. S. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29270-3 · Cited by 662
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Drug Transfer and Metabolism by the Human Placenta
Syme, M. R., Paxton, J. W., & Keelan, J. A. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443080-00001 · Cited by 634
Herb-Drug Interactions: A Literature Review
Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., Heng, P. W. S., Chan, E., Duan, W., Koh, H. L., & Zhou, S. (2005) · Drugs · doi:10.2165/00003495-200565090-00005 · Cited by 633
The Challenge of Viral Reservoirs in HIV-1 Infection
Blankson, J. N., Persaud, D., & Siliciano, R. F. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104024 · Cited by 627
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
OATP and P-Glycoprotein Transporters Mediate the Cellular Uptake and Excretion of Fexofenadine
Cvetkovic, M., Leake, B., Fromm, M. F., Wilkinson, G. R., & Kim, R. B. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15235-x · Cited by 597
Self-citationImportance of P-glycoprotein at blood–tissue barriers
Fromm, M. F. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.06.002 · Cited by 592
Self-citationChan, L. M. S., Lowes, S., & Hirst, B. H. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.07.003 · Cited by 582
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 575
Self-citationHirsch, M. S., Günthard, H. F., Schapiro, J. M., Brun‐Vézinet, F., Clotet, B., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Mellors, J. W., Pillay, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/589297 · Cited by 573
Neurological complications of HIV infection
McArthur, J. C., Brew, B. J., & Nath, A. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70165-4 · Cited by 554
Pierson, T., McArthur, J., & Siliciano, R. F. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.665 · Cited by 545
Drug Transporters in the Central Nervous System: Brain Barriers and Brain Parenchyma Considerations
Lee, G., Dallas, S., Hong, M., & Bendayan, R. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01513-8 · Cited by 539
Rao, V. V., Dahlheimer, J. L., Bardgett, M. E., Snyder, A. Z., Finch, R. A., Sartorelli, A. C., & Piwnica-Worms, D. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3900 · Cited by 531
The Caco-2 cell monolayer: usefulness and limitations
Sun, H., Chow, E. C., Liu, S., Du, Y., & Pang, K. S. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.395 · Cited by 527
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Brain barrier systems: a new frontier in metal neurotoxicological research
Zheng, W., Aschner, M., & Ghersi-Egea, J.-F. (2003) · Toxicology and Applied Pharmacology · doi:10.1016/s0041-008x(03)00251-5 · Cited by 507
Transporters and drug therapy: Implications for drug disposition and disease
HO, R., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.05.011 · Cited by 502
Self-citationImpact of Drug Transporter Studies on Drug Discovery and Development
Mizuno, N., Niwa, T., Yotsumoto, Y., & Sugiyama, Y. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.1 · Cited by 490
Ritonavir: Clinical Pharmacokinetics and Interactions with Other Anti-HIV Agents
Hsu, A., Granneman, G. R., & Bertz, R. J. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835040-00002 · Cited by 483
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Self-citationRobbiani, D. F., Finch, R. A., Jäger, D., Muller, W. A., Sartorelli, A. C., & Randolph, G. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00179-3 · Cited by 454
Human immunodeficiency virus‐associated neurocognitive disorders: Mind the gap
McArthur, J. C., Steiner, J., Sacktor, N., & Nath, A. (2010) · Annals of Neurology · doi:10.1002/ana.22053 · Cited by 445
Custodio, J. M., Wu, C.-Y., & Benet, L. Z. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.08.043 · Cited by 434
Increased drug delivery to the brain by P-glycoprotein inhibition
Sadeque, A. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.109156 · Cited by 426
Role of transport proteins in drug absorption, distribution and excretion
Ayrton, A., & Morgan, P. (2001) · Xenobiotica · doi:10.1080/00498250110060969 · Cited by 421
Richman, D. D. (2001) · Nature · doi:10.1038/35073673 · Cited by 419
Cory Kalvass, J., & Maurer, T. S. (2002) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.325 · Cited by 412
Ameyaw, M.-M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G. O., Githang'a, J., Indalo, A., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00005 · Cited by 409
HIV-1 Infection and Low Steady State Viral Loads
Callaway, D. (2002) · Bulletin of Mathematical Biology · doi:10.1006/bulm.2001.0266 · Cited by 402
Fromm, M. F., Kim, R. B., Stein, C. M., Wilkinson, G. R., & Roden, D. M. (1999) · Circulation · doi:10.1161/01.cir.99.4.552 · Cited by 402
Self-citationChoo, E. F., Leake, B., Wandel, C., Imamura, H., Wood, A. J. J., Wilkinson, G. R., & Kim, R. B. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15144-6 · Cited by 395
Self-citationMultidrug resistance transporters and modulation
Tan, B., Piwnica-Worms, D., & Ratner, L. (2000) · Current Opinion in Oncology · doi:10.1097/00001622-200009000-00011 · Cited by 384
Drugs as P-glycoprotein substrates, inhibitors, and inducers
Kim, R. B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120001389 · Cited by 382
Self-citationErickson, M. A., & Banks, W. A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014647 · Cited by 378
Hitzl, M., Drescher, S., van der Kuip, H., Schäffeler, E., Fischer, J., Schwab, M., Eichelbaum, M., & Fromm, M. F. (2001) · Pharmacogenetics · doi:10.1097/00008571-200106000-00003 · Cited by 374
Self-citationTransporter-Mediated Permeation of Drugs Across the Blood–Brain Barrier
Tamai, I., & Tsuji, A. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200011)89:11<1371::aid-jps1>3.0.co;2-d · Cited by 363
Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications
Hong, S., & Banks, W. A. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.10.008 · Cited by 360
Smit, J. W., Huisman, M. T., van Tellingen, O., Wiltshire, H. R., & Schinkel, A. H. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7963 · Cited by 352
The importance of plasma protein binding in drug discovery
Trainor, G. L. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.1.51 · Cited by 348
Cellular Reservoirs of HIV-1 and their Role in Viral Persistence
Alexaki, A., Liu, Y., & Wigdahl, B. (2008) · Current HIV Research · doi:10.2174/157016208785861195 · Cited by 341
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
ABC of oral bioavailability: transporters as gatekeepers in the gut
Dietrich, C. G., Geier, A., & Oude Elferink, R. P. J. (2003) · Gut · doi:10.1136/gut.52.12.1788 · Cited by 317
Drug–drug interaction mediated by inhibition and induction of P-glycoprotein
Lin, J. H. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00171-0 · Cited by 309
Wolking, S., Schaeffeler, E., Lerche, H., Schwab, M., & Nies, A. T. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0267-1 · Cited by 309
Genetic Polymorphisms of the Human MDR1 Drug Transporter
Schwab, M., Eichelbaum, M., & Fromm, M. F. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140233 · Cited by 308
Self-citationXenobiotic Transport across Isolated Brain Microvessels Studied by Confocal Microscopy
Miller, D. S., Nobmann, S. N., Gutmann, H., Toeroek, M., Drewe, J., & Fricker, G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12708-3 · Cited by 307
Drug efflux transporters in the CNS
Sun, H., Dai, H., Shaik, N., & Elmquist, W. F. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00172-2 · Cited by 304
High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery
White, R. E. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.133 · Cited by 304
Drug–Grapefruit Juice Interactions
Kane, G. C., & Lipsky, J. J. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.9.933 · Cited by 301
Schrager, L. K. (1998) · JAMA · doi:10.1001/jama.280.1.67 · Cited by 301
Havlir, D. V. (2000) · JAMA · doi:10.1001/jama.283.2.229 · Cited by 297
Controversies in HIV-associated neurocognitive disorders
Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., & Solomon, T. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70137-1 · Cited by 294
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
Self-citationIntestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery
Benet, L. Z., Izumi, T., Zhang, Y., Silverman, J. A., & Wacher, V. J. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00034-6 · Cited by 292
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Inhibition of P-Glycoprotein by Newer Antidepressants
Weiss, J., Dormann, S.-M. G., Martin-Facklam, M., Kerpen, C. J., Ketabi-Kiyanvash, N., & Haefeli, W. E. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046532 · Cited by 292
Suzuki, H., & Sugiyama, Y. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00178-0 · Cited by 291
Hepatobiliary transporters and drug‐induced cholestasis†
Pauli‐Magnus, C., & Meier, P. J. (2006) · Hepatology · doi:10.1002/hep.21359 · Cited by 285
Tang, K., Ngoi, S.-M., Gwee, P.-C., Chua, J. M. Z., Lee, E. J. D., Chong, S. S., & Lee, C. G. L. (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00004 · Cited by 285
Potential Role of Drug Transporters in the Pathogenesis of Medically Intractable Epilepsy
Kwan, P., & Brodie, M. J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.31904.x · Cited by 281
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
The Effect of Rifampin Treatment on Intestinal Expression of Human MRP Transporters
Fromm, M. F., Kauffmann, H.-M., Fritz, P., Burk, O., Kroemer, H. K., Warzok, R. W., Eichelbaum, M., Siegmund, W., & Schrenk, D. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64794-3 · Cited by 277
Self-citationSASONGKO, L., LINK, J., MUZI, M., MANKOFF, D., YANG, X., COLLIER, A., SHONER, S., & UNADKAT, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.022 · Cited by 271
The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts
Chandra, P., & Brouwer, K. L. R. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000026420.79421.8f · Cited by 266
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
Self-citationvon Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Self-citationClassification Analysis of P-Glycoprotein Substrate Specificity
Didziapetris, R., Japertas, P., Avdeef, A., & Petrauskas, A. (2003) · Journal of Drug Targeting · doi:10.1080/10611860310001648248 · Cited by 253
Synonymous Mutations and Ribosome Stalling Can Lead to Altered Folding Pathways and Distinct Minima
Tsai, C.-J., Sauna, Z. E., Kimchi-Sarfaty, C., Ambudkar, S. V., Gottesman, M. M., & Nussinov, R. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.08.012 · Cited by 252
Furuno, T., Landi, M.-T., Ceroni, M., Caporaso, N., Bernucci, I., Nappi, G., Martignoni, E., Schaeffeler, E., Eichelbaum, M., Schwab, M., et al. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00004 · Cited by 178
(1998) · PubMed · Cited by 176
Bardsley-Elliot (2000) · doi:10.2165/00003495-200059030-00014 · Cited by 127
“Nelfinavir interacts with the multidrug transporter protein MDR1, an efflux pump protein which limits uptake of drugs into major organs and the CNS.”
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Clinically Significant Drug Interactions with Atypical Antipsychotics
Kennedy, W. K., Jann, M. W., & Kutscher, E. C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0114-6 · Cited by 95
“Probenecid is a known UGT inhibitor and was coadministered with olanzapine and risperidone in a study of 12 healthy volunteers [17].”
BackgroundAntiretroviral and immunosuppressive drug-drug interactions: An update
Izzedine, H., Launay-Vacher, V., Baumelou, A., & Deray, G. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00772.x · Cited by 86
(2004) · PubMed · Cited by 66
Past, Present, and Future Drug Delivery Systems for Antiretrovirals
Kirtane, A. R., Langer, R., & Traverso, G. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.09.015 · Cited by 28
Metadata
- Authors
- Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J., Roden, D. M., & Wilkinson, G. R.
- Venue
- Journal of Clinical Investigation
- Published
- 1998-01-15
- Volume
- 101
- Issue
- 2
- Pages
- 289-294
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2131403498
- Cited by
- 1,054
- References
- 23
- FWCI
- 33.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.